Examples of other predictive biomarkers with clinical relevance to targeted therapies are the BCR-ABL tyrosine kinase, a fusion gene that is associated with Philadelphia chromosome in chronic myeloid leukemia [67], KRAS mutations in colorectal cancer [68], and a mutation in the KIT proto-oncogene in the gastrointestinal stromal tumor [69]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.